1548 ET -- Revvity still has areas of continued end-market softness, as its slower-than-expected instrument recovery led management to reduce its guidance for the year, Baird analysts say in a research note. The provider of research-and-discovery, testing and other services to the medical industry also posted a mixed revenue performance as consumer spending on instruments continues to be constrained, particularly in China. Still, the analysts say they remain constructive on the medium-term setup at the current valuation. Shares rise 0.5% to $125.38. (sabela.ojea@wsj.com)
(END) Dow Jones Newswires
November 05, 2024 15:51 ET (20:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.